Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical businesses, including the makers of Xarelto, have a duty to ensure that their drugs are reasonably safe for use – and failure to do so could be grounds for compensation. Our lawyers are operating hard to acquire those hurt by the drug the compensation they’re entitled to.
While bleeding is a frequent complication related with anticoagulants, it has been alleged that Xarelto is more hazardous than conventional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, inside the event of an emergency, sufferers may be at risk for irreversible bleeding problems, such as life-threatening internal and gastrointestinal hemorrhaging.
Should you or even a loved a single suffered a critical bleeding event soon after taking Xarelto, you may have legal recourse. For a lot more information, contact us these days to have your case reviewed, cost-free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future health-related bills, lost wages, discomfort and suffering and, in circumstances of death, funeral expenses. Additionally, they may be looking for punitive damages, that are usually awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can xarelto cause internal bleeding be reversed using vitamin K, there is no antidote available for Xarelto. Simply because of this, the lawsuits claim, doctors have no effective indicates of stopping Xarelto users from bleeding inside the event of an emergency. Plaintiffs within the lawsuits allege severe and fatal injuries, like cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior inside the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a safe anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for a lot more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.